Methodology of antiemetic trials: A review
- 1 February 1991
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 2 (2) , 107-114
- https://doi.org/10.1093/oxfordjournals.annonc.a057871
Abstract
Chemotherapy-related nausea and vomiting can be controlled with available antiemetics in a high percentage of patients, while emesis remains a critical problem in some subgroups and with certain drugs. In the ceaseless attempt to find newer drugs and better treatment modalities, a sound methodology in antiemetic research is essential. Several factors should always be considered when planning an antiemetic trial: first, the different emetic power of various chemotherapy agents, their dosages and route and schedule of administration and second, the type of antiemetic used, its dosage and timing, and its possible combination with other antiemetics. Important factors which influence outcome but which are often under-evaluated are those related to patient population such as age, gender, and previous experience with chemotherapy. Considering the relevance of subjective phenomena in nausea and vomiting, it is essential that any study be randomized and double blinded. The parallel type of study design is preferable to the cross-over and a large number of patients is usually required to achieve meaningful results. Efficacy and toxicity should be properly evaluated by trained personnel in a standardized way, using a validated, relatively simple methodology.Keywords
This publication has 26 references indexed in Scilit:
- Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1989
- Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.Journal of Clinical Oncology, 1987
- Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Clinical evaluation of the simultaneous blockade of the dopamine D-2, Histamine H-1, and muscarinic cholinergic receptors in cancer chemotherapy-induced emesis: Results of a controlled trialCancer Chemotherapy and Pharmacology, 1986
- The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinumGynecologic Oncology, 1985
- Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over studyEuropean Journal of Cancer and Clinical Oncology, 1984
- Methodologic issues in trials of antiemetics.Journal of Clinical Oncology, 1984
- The Assessment of Nausea and VomitingCancer, 1984
- Delta-9-Tetrahydrocannabinol in Cancer Chemotherapy: Research Problems and IssuesAnnals of Internal Medicine, 1983
- ANTIEMETIC DRUG COMBINATIONS IN ADVANCED CANCERThe Lancet, 1982